| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 104 | 2023 | 839 | 13.260 |
Why?
|
| Living Donors | 29 | 2022 | 160 | 5.050 |
Why?
|
| Immunosuppressive Agents | 44 | 2019 | 514 | 4.940 |
Why?
|
| Graft Rejection | 49 | 2021 | 458 | 4.490 |
Why?
|
| Graft Survival | 53 | 2022 | 465 | 4.390 |
Why?
|
| Liver Transplantation | 30 | 2018 | 400 | 3.230 |
Why?
|
| Kidney Failure, Chronic | 18 | 2023 | 365 | 2.590 |
Why?
|
| Pancreas Transplantation | 17 | 2021 | 71 | 2.210 |
Why?
|
| Quality Improvement | 6 | 2022 | 413 | 2.200 |
Why?
|
| Transplant Recipients | 10 | 2018 | 109 | 2.070 |
Why?
|
| Postoperative Complications | 19 | 2020 | 1615 | 2.060 |
Why?
|
| Renal Insufficiency | 7 | 2020 | 121 | 1.810 |
Why?
|
| Middle Aged | 100 | 2022 | 21119 | 1.810 |
Why?
|
| Adult | 105 | 2022 | 21379 | 1.740 |
Why?
|
| Tissue and Organ Procurement | 9 | 2022 | 164 | 1.640 |
Why?
|
| Retrospective Studies | 67 | 2022 | 7268 | 1.640 |
Why?
|
| Female | 133 | 2021 | 38021 | 1.580 |
Why?
|
| Male | 122 | 2021 | 37283 | 1.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2022 | 766 | 1.490 |
Why?
|
| Humans | 169 | 2023 | 68549 | 1.440 |
Why?
|
| Healthcare Disparities | 11 | 2023 | 378 | 1.410 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 161 | 1.370 |
Why?
|
| Tissue Donors | 11 | 2022 | 195 | 1.360 |
Why?
|
| Antibodies, Monoclonal | 13 | 2017 | 511 | 1.270 |
Why?
|
| Antilymphocyte Serum | 8 | 2017 | 52 | 1.270 |
Why?
|
| Tacrolimus | 9 | 2019 | 127 | 1.260 |
Why?
|
| Treatment Outcome | 52 | 2022 | 7028 | 1.230 |
Why?
|
| Health Services Accessibility | 8 | 2020 | 581 | 1.220 |
Why?
|
| Aged | 49 | 2022 | 14842 | 1.170 |
Why?
|
| Sirolimus | 6 | 2017 | 118 | 1.140 |
Why?
|
| Health Education | 3 | 2017 | 279 | 1.050 |
Why?
|
| Waiting Lists | 7 | 2021 | 104 | 1.030 |
Why?
|
| Risk Factors | 43 | 2019 | 5720 | 0.970 |
Why?
|
| Adolescent | 33 | 2022 | 8904 | 0.970 |
Why?
|
| Health Literacy | 2 | 2015 | 62 | 0.950 |
Why?
|
| Follow-Up Studies | 30 | 2019 | 3256 | 0.940 |
Why?
|
| Patient Readmission | 9 | 2017 | 267 | 0.930 |
Why?
|
| Patient Selection | 5 | 2020 | 592 | 0.930 |
Why?
|
| Delayed Graft Function | 7 | 2022 | 39 | 0.920 |
Why?
|
| Decision Making | 3 | 2016 | 410 | 0.910 |
Why?
|
| Mycophenolic Acid | 8 | 2017 | 62 | 0.910 |
Why?
|
| Medication Errors | 3 | 2014 | 116 | 0.890 |
Why?
|
| Pharmacists | 2 | 2015 | 125 | 0.890 |
Why?
|
| Focus Groups | 6 | 2019 | 247 | 0.880 |
Why?
|
| Young Adult | 25 | 2022 | 5710 | 0.880 |
Why?
|
| Induction Chemotherapy | 3 | 2017 | 39 | 0.850 |
Why?
|
| South Carolina | 17 | 2020 | 2752 | 0.830 |
Why?
|
| Cross-Sectional Studies | 14 | 2022 | 2265 | 0.830 |
Why?
|
| Health Status Disparities | 5 | 2018 | 326 | 0.780 |
Why?
|
| Surgical Procedures, Operative | 3 | 2021 | 124 | 0.780 |
Why?
|
| Surveys and Questionnaires | 11 | 2021 | 2798 | 0.780 |
Why?
|
| Kidney | 11 | 2022 | 945 | 0.770 |
Why?
|
| Continuity of Patient Care | 2 | 2013 | 170 | 0.760 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 22 | 0.760 |
Why?
|
| Proportional Hazards Models | 12 | 2018 | 791 | 0.740 |
Why?
|
| Altruism | 2 | 2019 | 24 | 0.740 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 27 | 0.740 |
Why?
|
| End Stage Liver Disease | 2 | 2018 | 60 | 0.730 |
Why?
|
| Hospital Administration | 1 | 2020 | 43 | 0.730 |
Why?
|
| United States | 28 | 2022 | 7338 | 0.710 |
Why?
|
| Attitude | 2 | 2022 | 121 | 0.690 |
Why?
|
| Antiviral Agents | 6 | 2017 | 211 | 0.680 |
Why?
|
| Time Factors | 30 | 2019 | 4655 | 0.680 |
Why?
|
| Morals | 1 | 2019 | 27 | 0.670 |
Why?
|
| Patient Navigation | 2 | 2016 | 30 | 0.660 |
Why?
|
| Receptors, Interleukin-2 | 4 | 2016 | 42 | 0.650 |
Why?
|
| Adaptation, Psychological | 3 | 2014 | 447 | 0.650 |
Why?
|
| Attitude to Health | 6 | 2015 | 403 | 0.650 |
Why?
|
| Immunoglobulin G | 5 | 2017 | 481 | 0.650 |
Why?
|
| Muscle Weakness | 1 | 2018 | 26 | 0.630 |
Why?
|
| Frail Elderly | 1 | 2018 | 31 | 0.630 |
Why?
|
| Longitudinal Studies | 17 | 2021 | 1054 | 0.620 |
Why?
|
| Frailty | 1 | 2018 | 34 | 0.610 |
Why?
|
| Liver Failure | 4 | 2013 | 27 | 0.610 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 376 | 0.610 |
Why?
|
| Telemedicine | 4 | 2021 | 699 | 0.610 |
Why?
|
| Colon | 1 | 2018 | 168 | 0.600 |
Why?
|
| Referral and Consultation | 2 | 2020 | 383 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2019 | 529 | 0.590 |
Why?
|
| Survival Rate | 10 | 2018 | 1055 | 0.580 |
Why?
|
| Health Care Rationing | 1 | 2017 | 32 | 0.570 |
Why?
|
| Hospital Costs | 2 | 2017 | 117 | 0.570 |
Why?
|
| Length of Stay | 14 | 2017 | 780 | 0.560 |
Why?
|
| Financing, Personal | 1 | 2016 | 17 | 0.560 |
Why?
|
| Patient Education as Topic | 6 | 2015 | 424 | 0.560 |
Why?
|
| Organ Transplantation | 3 | 2013 | 110 | 0.550 |
Why?
|
| Medication Reconciliation | 2 | 2013 | 18 | 0.550 |
Why?
|
| Social Media | 1 | 2016 | 58 | 0.520 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 69 | 0.520 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 52 | 0.510 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 1046 | 0.510 |
Why?
|
| Thrombosis | 6 | 2014 | 218 | 0.510 |
Why?
|
| Cytomegalovirus Infections | 5 | 2017 | 69 | 0.510 |
Why?
|
| Liver Diseases | 6 | 2008 | 193 | 0.510 |
Why?
|
| Medical Records | 1 | 2015 | 121 | 0.510 |
Why?
|
| Nephrectomy | 8 | 2014 | 103 | 0.500 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2009 | 32 | 0.500 |
Why?
|
| Health Policy | 1 | 2017 | 221 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2017 | 151 | 0.500 |
Why?
|
| Information Dissemination | 1 | 2016 | 113 | 0.490 |
Why?
|
| BK Virus | 3 | 2018 | 17 | 0.490 |
Why?
|
| Polyomavirus Infections | 3 | 2018 | 17 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2014 | 148 | 0.480 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 4843 | 0.470 |
Why?
|
| Hepatitis C | 3 | 2022 | 114 | 0.470 |
Why?
|
| Minority Groups | 3 | 2015 | 196 | 0.470 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 136 | 0.460 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 498 | 0.460 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 32 | 0.450 |
Why?
|
| Benchmarking | 1 | 2013 | 91 | 0.450 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 191 | 0.440 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.440 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 32 | 0.430 |
Why?
|
| Medication Adherence | 4 | 2016 | 335 | 0.420 |
Why?
|
| Patient Compliance | 2 | 2014 | 402 | 0.420 |
Why?
|
| Transplantation | 1 | 2012 | 23 | 0.410 |
Why?
|
| Drugs, Generic | 1 | 2012 | 17 | 0.410 |
Why?
|
| Receptors, Transferrin | 4 | 1999 | 18 | 0.410 |
Why?
|
| Isoxazoles | 1 | 2012 | 22 | 0.410 |
Why?
|
| Patient Care Management | 1 | 2012 | 40 | 0.410 |
Why?
|
| Cohort Studies | 10 | 2019 | 2356 | 0.410 |
Why?
|
| Perioperative Care | 1 | 2013 | 100 | 0.410 |
Why?
|
| Mesenteric Veins | 1 | 2011 | 10 | 0.410 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2011 | 8 | 0.410 |
Why?
|
| Arteriovenous Fistula | 1 | 2011 | 25 | 0.400 |
Why?
|
| Algorithms | 5 | 2020 | 1195 | 0.400 |
Why?
|
| Patient Dropouts | 1 | 2012 | 98 | 0.400 |
Why?
|
| Kidney Diseases | 5 | 2018 | 307 | 0.390 |
Why?
|
| Apolipoprotein L1 | 2 | 2022 | 16 | 0.390 |
Why?
|
| Health Personnel | 1 | 2014 | 286 | 0.390 |
Why?
|
| Cyclosporine | 7 | 2017 | 121 | 0.390 |
Why?
|
| Registries | 6 | 2018 | 730 | 0.390 |
Why?
|
| Aneurysm, False | 1 | 2011 | 60 | 0.390 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 445 | 0.380 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2011 | 185 | 0.380 |
Why?
|
| Prospective Studies | 15 | 2017 | 3703 | 0.380 |
Why?
|
| Prognosis | 8 | 2019 | 2093 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2013 | 339 | 0.370 |
Why?
|
| Policy | 2 | 2022 | 58 | 0.370 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.360 |
Why?
|
| Transplantation, Homologous | 10 | 2019 | 242 | 0.360 |
Why?
|
| Fear | 4 | 2014 | 239 | 0.350 |
Why?
|
| Blood Transfusion | 1 | 2011 | 205 | 0.350 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2011 | 123 | 0.350 |
Why?
|
| Logistic Models | 6 | 2017 | 1419 | 0.330 |
Why?
|
| Biomarkers | 5 | 2018 | 1593 | 0.320 |
Why?
|
| Qualitative Research | 3 | 2019 | 369 | 0.320 |
Why?
|
| Blood Glucose | 5 | 2018 | 631 | 0.320 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 38 | 0.310 |
Why?
|
| Cholestasis | 2 | 2007 | 90 | 0.310 |
Why?
|
| Child | 16 | 2015 | 6401 | 0.300 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2007 | 8 | 0.300 |
Why?
|
| Hyperglycemia | 2 | 2014 | 158 | 0.300 |
Why?
|
| T-Lymphocytes | 5 | 1999 | 597 | 0.300 |
Why?
|
| Hypertension | 6 | 2016 | 1533 | 0.290 |
Why?
|
| Health Care Costs | 3 | 2015 | 346 | 0.290 |
Why?
|
| Kidney Function Tests | 5 | 2019 | 114 | 0.290 |
Why?
|
| ROC Curve | 4 | 2016 | 392 | 0.290 |
Why?
|
| Heart Transplantation | 8 | 1999 | 328 | 0.280 |
Why?
|
| Incidence | 11 | 2019 | 1582 | 0.280 |
Why?
|
| Calcineurin Inhibitors | 2 | 2017 | 24 | 0.280 |
Why?
|
| Age Factors | 7 | 2021 | 1860 | 0.280 |
Why?
|
| Osteoporosis | 1 | 2007 | 88 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 467 | 0.270 |
Why?
|
| Diabetes Mellitus | 5 | 2016 | 694 | 0.270 |
Why?
|
| Antigens, CD | 5 | 1998 | 230 | 0.270 |
Why?
|
| Embolization, Therapeutic | 2 | 2011 | 150 | 0.260 |
Why?
|
| Antigens, Differentiation | 2 | 1996 | 49 | 0.260 |
Why?
|
| Immunoconjugates | 2 | 1996 | 26 | 0.260 |
Why?
|
| Creatinine | 6 | 2016 | 243 | 0.260 |
Why?
|
| Income | 3 | 2016 | 165 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 2077 | 0.260 |
Why?
|
| Drug Administration Schedule | 5 | 2017 | 567 | 0.250 |
Why?
|
| Child, Preschool | 10 | 2015 | 3187 | 0.240 |
Why?
|
| Risk Assessment | 9 | 2019 | 2004 | 0.240 |
Why?
|
| Renal Dialysis | 4 | 2023 | 174 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 1085 | 0.240 |
Why?
|
| Liver Failure, Acute | 1 | 2004 | 49 | 0.240 |
Why?
|
| Ganciclovir | 3 | 2017 | 27 | 0.240 |
Why?
|
| Opportunistic Infections | 3 | 2018 | 33 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 546 | 0.230 |
Why?
|
| Educational Status | 2 | 2016 | 273 | 0.230 |
Why?
|
| Liver | 7 | 2019 | 1118 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 536 | 0.230 |
Why?
|
| Diabetes Complications | 3 | 2014 | 249 | 0.230 |
Why?
|
| Epitopes | 4 | 2016 | 146 | 0.230 |
Why?
|
| Drug Therapy, Combination | 7 | 2017 | 648 | 0.220 |
Why?
|
| Cadaver | 4 | 2004 | 136 | 0.220 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 442 | 0.220 |
Why?
|
| Blood Pressure | 5 | 2015 | 1449 | 0.210 |
Why?
|
| Linear Models | 2 | 2015 | 521 | 0.210 |
Why?
|
| Ischemia | 2 | 2002 | 229 | 0.210 |
Why?
|
| Splenic Artery | 1 | 2002 | 16 | 0.210 |
Why?
|
| Laparoscopy | 5 | 2008 | 237 | 0.210 |
Why?
|
| Academic Medical Centers | 3 | 2012 | 281 | 0.210 |
Why?
|
| Hospitals | 2 | 2022 | 265 | 0.200 |
Why?
|
| Patient Care Team | 2 | 2015 | 311 | 0.200 |
Why?
|
| Reoperation | 6 | 2018 | 467 | 0.200 |
Why?
|
| Social Support | 2 | 2014 | 423 | 0.200 |
Why?
|
| Liver Cirrhosis | 3 | 2015 | 301 | 0.200 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 166 | 0.200 |
Why?
|
| Spleen | 1 | 2002 | 301 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 134 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1745 | 0.190 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 17 | 0.190 |
Why?
|
| Motivation | 3 | 2019 | 561 | 0.190 |
Why?
|
| Immunity, Cellular | 3 | 1998 | 80 | 0.190 |
Why?
|
| Southeastern United States | 2 | 2014 | 281 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 186 | 0.180 |
Why?
|
| Antihypertensive Agents | 2 | 2015 | 497 | 0.180 |
Why?
|
| Heparin | 2 | 2014 | 205 | 0.180 |
Why?
|
| HLA Antigens | 2 | 2016 | 82 | 0.180 |
Why?
|
| Transplantation Chimera | 1 | 2000 | 10 | 0.180 |
Why?
|
| Preoperative Period | 2 | 2018 | 50 | 0.180 |
Why?
|
| Mice, Inbred CBA | 7 | 1999 | 107 | 0.180 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 938 | 0.180 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1465 | 0.180 |
Why?
|
| Infant | 8 | 2015 | 2891 | 0.170 |
Why?
|
| Nursing Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| Biopsy | 8 | 2018 | 539 | 0.170 |
Why?
|
| Withholding Treatment | 2 | 2016 | 35 | 0.170 |
Why?
|
| Resource Allocation | 1 | 2019 | 35 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 5 | 2019 | 274 | 0.170 |
Why?
|
| Grounded Theory | 1 | 2019 | 20 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2016 | 714 | 0.170 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2006 | 49 | 0.160 |
Why?
|
| Muromonab-CD3 | 2 | 2017 | 8 | 0.160 |
Why?
|
| B7-1 Antigen | 1 | 1998 | 20 | 0.160 |
Why?
|
| Fibrinolytic Agents | 2 | 2014 | 377 | 0.160 |
Why?
|
| Awareness | 2 | 2011 | 81 | 0.160 |
Why?
|
| Trust | 2 | 2011 | 75 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 349 | 0.160 |
Why?
|
| Area Under Curve | 2 | 2016 | 238 | 0.150 |
Why?
|
| Alemtuzumab | 1 | 2017 | 10 | 0.150 |
Why?
|
| Hepatectomy | 2 | 2008 | 58 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 1998 | 63 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 163 | 0.150 |
Why?
|
| CD2 Antigens | 2 | 1996 | 8 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2017 | 621 | 0.150 |
Why?
|
| Bradycardia | 1 | 1997 | 45 | 0.150 |
Why?
|
| Body Mass Index | 3 | 2017 | 866 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 62 | 0.150 |
Why?
|
| Nephrons | 1 | 2017 | 17 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 438 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2017 | 19 | 0.140 |
Why?
|
| Medical Assistance | 1 | 2016 | 9 | 0.140 |
Why?
|
| CD28 Antigens | 1 | 1996 | 12 | 0.140 |
Why?
|
| No-Show Patients | 1 | 2016 | 9 | 0.140 |
Why?
|
| Short Bowel Syndrome | 1 | 1996 | 15 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 1996 | 25 | 0.140 |
Why?
|
| Second Messenger Systems | 1 | 1996 | 53 | 0.140 |
Why?
|
| Sex Factors | 5 | 2015 | 1265 | 0.140 |
Why?
|
| Desensitization, Immunologic | 1 | 1996 | 25 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2016 | 17 | 0.140 |
Why?
|
| Membrane Glycoproteins | 2 | 1998 | 370 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2016 | 35 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 298 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 163 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 42 | 0.140 |
Why?
|
| Intestine, Small | 1 | 1996 | 89 | 0.140 |
Why?
|
| Steroids | 1 | 2016 | 84 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 378 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 492 | 0.130 |
Why?
|
| Age Distribution | 1 | 2016 | 319 | 0.130 |
Why?
|
| Health Status | 2 | 2016 | 429 | 0.130 |
Why?
|
| Social Class | 1 | 2016 | 127 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 448 | 0.130 |
Why?
|
| Diabetic Nephropathies | 3 | 2013 | 161 | 0.130 |
Why?
|
| Cause of Death | 2 | 2015 | 241 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 93 | 0.130 |
Why?
|
| Professional Role | 1 | 2015 | 80 | 0.130 |
Why?
|
| Hospitalization | 2 | 2018 | 977 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 6 | 1999 | 532 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2017 | 52 | 0.130 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 79 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1851 | 0.120 |
Why?
|
| Kidney Tubules | 1 | 2015 | 80 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2015 | 66 | 0.120 |
Why?
|
| Hepatic Artery | 3 | 2012 | 25 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 1999 | 79 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 59 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 334 | 0.120 |
Why?
|
| Biliary Tract Diseases | 1 | 2014 | 50 | 0.120 |
Why?
|
| Health Services Research | 1 | 2015 | 209 | 0.120 |
Why?
|
| Isoantigens | 3 | 1999 | 26 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 235 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2017 | 374 | 0.120 |
Why?
|
| Superior Sagittal Sinus | 1 | 2013 | 8 | 0.120 |
Why?
|
| Everolimus | 1 | 2013 | 26 | 0.120 |
Why?
|
| Comorbidity | 3 | 2016 | 1425 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 444 | 0.120 |
Why?
|
| Thiazides | 1 | 2013 | 6 | 0.120 |
Why?
|
| Self Administration | 1 | 2015 | 419 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 7 | 1999 | 2791 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1549 | 0.110 |
Why?
|
| Coagulants | 1 | 2013 | 4 | 0.110 |
Why?
|
| Factor VIIa | 1 | 2013 | 25 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 96 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2017 | 880 | 0.110 |
Why?
|
| Patient Participation | 1 | 2014 | 145 | 0.110 |
Why?
|
| Drug Monitoring | 2 | 2012 | 107 | 0.110 |
Why?
|
| Cell Phone | 1 | 2013 | 43 | 0.110 |
Why?
|
| Crotonates | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 4 | 0.100 |
Why?
|
| Toluidines | 1 | 2012 | 5 | 0.100 |
Why?
|
| Medical History Taking | 1 | 2013 | 94 | 0.100 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 84 | 0.100 |
Why?
|
| Biotransformation | 1 | 2012 | 69 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2012 | 52 | 0.100 |
Why?
|
| Medically Underserved Area | 1 | 2012 | 85 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 68 | 0.100 |
Why?
|
| Hepacivirus | 3 | 2022 | 90 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 272 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 100 | 0.100 |
Why?
|
| Viral Load | 1 | 2012 | 127 | 0.100 |
Why?
|
| Cytokines | 5 | 1999 | 866 | 0.100 |
Why?
|
| Mice | 10 | 1999 | 8474 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2017 | 1341 | 0.100 |
Why?
|
| Pain, Postoperative | 3 | 2020 | 214 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2011 | 42 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2011 | 25 | 0.100 |
Why?
|
| Aspirin | 1 | 2012 | 295 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 188 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 420 | 0.090 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 320 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2006 | 169 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2011 | 86 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2013 | 294 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 572 | 0.090 |
Why?
|
| Insulin | 2 | 2012 | 617 | 0.090 |
Why?
|
| Health Surveys | 1 | 2012 | 488 | 0.090 |
Why?
|
| Sepsis | 2 | 2009 | 233 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 772 | 0.090 |
Why?
|
| Half-Life | 1 | 2009 | 96 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 122 | 0.090 |
Why?
|
| Liver Circulation | 2 | 2002 | 40 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2015 | 659 | 0.090 |
Why?
|
| Protein C | 1 | 2009 | 4 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 2000 | 94 | 0.090 |
Why?
|
| Depression | 1 | 2016 | 942 | 0.080 |
Why?
|
| Veterans | 1 | 2016 | 904 | 0.080 |
Why?
|
| RNA, Messenger | 5 | 1999 | 1663 | 0.080 |
Why?
|
| Lymphocyte Activation | 4 | 1999 | 397 | 0.080 |
Why?
|
| Self Efficacy | 2 | 2021 | 199 | 0.080 |
Why?
|
| Animals | 12 | 2014 | 20880 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.080 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 7 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2015 | 384 | 0.080 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 39 | 0.080 |
Why?
|
| Recurrence | 3 | 2015 | 948 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2007 | 39 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1998 | 9 | 0.070 |
Why?
|
| Alprostadil | 2 | 1996 | 20 | 0.070 |
Why?
|
| Transplantation Immunology | 2 | 1998 | 11 | 0.070 |
Why?
|
| Eligibility Determination | 1 | 2006 | 31 | 0.070 |
Why?
|
| Social Perception | 1 | 2006 | 44 | 0.070 |
Why?
|
| North Carolina | 1 | 2006 | 224 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2007 | 186 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.070 |
Why?
|
| Abatacept | 2 | 1996 | 17 | 0.070 |
Why?
|
| CTLA-4 Antigen | 2 | 1996 | 45 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2006 | 67 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 209 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.060 |
Why?
|
| Anxiety | 2 | 2021 | 422 | 0.060 |
Why?
|
| Family | 1 | 2007 | 293 | 0.060 |
Why?
|
| Fibrosis | 2 | 2018 | 371 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2017 | 307 | 0.060 |
Why?
|
| Prednisone | 2 | 2014 | 104 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2014 | 163 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 15 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 955 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2004 | 238 | 0.060 |
Why?
|
| Cytomegalovirus | 2 | 2017 | 63 | 0.060 |
Why?
|
| Adenovirus Infections, Human | 1 | 2003 | 4 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 742 | 0.060 |
Why?
|
| Syndrome | 2 | 2002 | 255 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 472 | 0.060 |
Why?
|
| Ribavirin | 1 | 2003 | 27 | 0.060 |
Why?
|
| Acyclovir | 2 | 2010 | 38 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 55 | 0.050 |
Why?
|
| Injections, Intravenous | 3 | 1998 | 215 | 0.050 |
Why?
|
| Dyslipidemias | 2 | 2014 | 98 | 0.050 |
Why?
|
| Chylous Ascites | 1 | 2002 | 11 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 13 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2021 | 24 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2001 | 10 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 67 | 0.050 |
Why?
|
| Angiography | 1 | 2002 | 194 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 95 | 0.050 |
Why?
|
| Catheterization | 1 | 2002 | 209 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 117 | 0.050 |
Why?
|
| Forecasting | 2 | 2019 | 277 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1449 | 0.050 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 9 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2000 | 98 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1996 | 66 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2020 | 159 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 652 | 0.040 |
Why?
|
| C-Peptide | 1 | 2018 | 23 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 1998 | 23 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 77 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2455 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 2222 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.040 |
Why?
|
| Colitis | 1 | 1999 | 156 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2017 | 24 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 951 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 266 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1998 | 304 | 0.040 |
Why?
|
| Urinary Bladder | 2 | 1998 | 108 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2017 | 43 | 0.040 |
Why?
|
| Cell Division | 1 | 1998 | 541 | 0.040 |
Why?
|
| Gardner Syndrome | 1 | 1996 | 3 | 0.040 |
Why?
|
| Fibromatosis, Aggressive | 1 | 1996 | 5 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 36 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 1994 | 489 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 1996 | 30 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 47 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 181 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2018 | 279 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.030 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1997 | 101 | 0.030 |
Why?
|
| Obesity | 1 | 2003 | 1074 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2014 | 344 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 349 | 0.030 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 1995 | 9 | 0.030 |
Why?
|
| Jugular Veins | 1 | 1995 | 37 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 568 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 946 | 0.030 |
Why?
|
| Face | 1 | 1995 | 46 | 0.030 |
Why?
|
| Atrophy | 1 | 2015 | 112 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 6 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 2 | 2010 | 65 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.030 |
Why?
|
| Employment | 1 | 2016 | 154 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 52 | 0.030 |
Why?
|
| Electrocardiography | 1 | 1997 | 601 | 0.030 |
Why?
|
| Dermatitis, Contact | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2015 | 42 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 8 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 216 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2013 | 275 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 1995 | 89 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 17 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 27 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 28 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 211 | 0.030 |
Why?
|
| Rats | 3 | 1999 | 5300 | 0.030 |
Why?
|
| Drug Costs | 1 | 2014 | 87 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 1994 | 72 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.030 |
Why?
|
| Research | 1 | 2015 | 214 | 0.030 |
Why?
|
| Urethra | 1 | 1994 | 56 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 69 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 180 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 254 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2013 | 21 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1995 | 215 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1993 | 69 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 509 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 155 | 0.030 |
Why?
|
| Coenzyme A Ligases | 1 | 1993 | 25 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1995 | 222 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 201 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2015 | 138 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 168 | 0.030 |
Why?
|
| Microbodies | 1 | 1993 | 60 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1993 | 133 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 579 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 25 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 729 | 0.030 |
Why?
|
| Propensity Score | 1 | 2013 | 116 | 0.030 |
Why?
|
| Hemostasis | 1 | 2012 | 32 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 929 | 0.030 |
Why?
|
| Hepatitis | 1 | 1992 | 25 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2013 | 91 | 0.030 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1992 | 14 | 0.030 |
Why?
|
| Bilirubin | 1 | 1992 | 51 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 87 | 0.030 |
Why?
|
| Morbidity | 1 | 1992 | 130 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 212 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.030 |
Why?
|
| Myocardium | 1 | 1998 | 1204 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 1992 | 137 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1993 | 123 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1993 | 182 | 0.030 |
Why?
|
| Self Report | 1 | 2014 | 370 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 316 | 0.030 |
Why?
|
| Health Resources | 1 | 1992 | 76 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2009 | 328 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2011 | 93 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 1991 | 45 | 0.020 |
Why?
|
| Aorta | 1 | 1993 | 316 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Organ Preservation | 1 | 1991 | 69 | 0.020 |
Why?
|
| Psychometrics | 1 | 2014 | 514 | 0.020 |
Why?
|
| Solutions | 1 | 1991 | 115 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1993 | 384 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 503 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1993 | 626 | 0.020 |
Why?
|
| Pregnancy | 1 | 1996 | 2334 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2010 | 34 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 239 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 373 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 390 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 361 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 279 | 0.020 |
Why?
|
| Glutathione | 1 | 1991 | 343 | 0.020 |
Why?
|
| APACHE | 1 | 2009 | 41 | 0.020 |
Why?
|
| Fimbriae, Bacterial | 1 | 1988 | 13 | 0.020 |
Why?
|
| Pyelonephritis | 1 | 1988 | 17 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 1988 | 47 | 0.020 |
Why?
|
| Hemangioma | 1 | 2008 | 51 | 0.020 |
Why?
|
| Cysts | 1 | 2008 | 70 | 0.020 |
Why?
|
| Hirudins | 1 | 2008 | 32 | 0.020 |
Why?
|
| Factor V | 1 | 2008 | 20 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2008 | 57 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2014 | 824 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2008 | 123 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1988 | 368 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2005 | 21 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 849 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2008 | 356 | 0.020 |
Why?
|
| Leukopenia | 1 | 2004 | 23 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2004 | 289 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 110 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 225 | 0.010 |
Why?
|
| Paracentesis | 1 | 2002 | 25 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1996 | 1738 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1993 | 1040 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1998 | 48 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 145 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1997 | 44 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1997 | 60 | 0.010 |
Why?
|
| Intestines | 1 | 1998 | 114 | 0.010 |
Why?
|
| Drainage | 1 | 1998 | 133 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 411 | 0.010 |
Why?
|
| Rehydration Solutions | 1 | 1996 | 5 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 25 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1996 | 47 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1996 | 15 | 0.010 |
Why?
|
| Portal Vein | 1 | 1996 | 46 | 0.010 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1996 | 31 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1998 | 682 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 658 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 1995 | 17 | 0.010 |
Why?
|
| Rupture | 1 | 1995 | 29 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 172 | 0.010 |
Why?
|
| Arm | 1 | 1995 | 59 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 737 | 0.010 |
Why?
|
| Veins | 1 | 1995 | 68 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 182 | 0.010 |
Why?
|
| CD48 Antigen | 1 | 1994 | 2 | 0.010 |
Why?
|
| Contact Inhibition | 1 | 1994 | 2 | 0.010 |
Why?
|
| CD58 Antigens | 1 | 1994 | 4 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1994 | 11 | 0.010 |
Why?
|
| Homozygote | 1 | 1994 | 119 | 0.010 |
Why?
|
| Receptors, Antigen | 1 | 1993 | 6 | 0.010 |
Why?
|
| Heterozygote | 1 | 1994 | 174 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 1997 | 334 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1995 | 291 | 0.010 |
Why?
|
| Life Tables | 1 | 1993 | 29 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 92 | 0.010 |
Why?
|
| Epithelium | 1 | 1993 | 172 | 0.010 |
Why?
|
| Ligands | 1 | 1994 | 317 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1993 | 44 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1993 | 104 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1992 | 23 | 0.010 |
Why?
|
| Michigan | 1 | 1992 | 68 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2324 | 0.010 |
Why?
|
| Necrosis | 1 | 1992 | 239 | 0.010 |
Why?
|
| Raffinose | 1 | 1991 | 28 | 0.010 |
Why?
|
| Allopurinol | 1 | 1991 | 36 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 114 | 0.010 |
Why?
|
| Adenosine | 1 | 1991 | 165 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1992 | 453 | 0.010 |
Why?
|
| Skin | 1 | 1993 | 451 | 0.010 |
Why?
|
| Adhesins, Escherichia coli | 1 | 1988 | 2 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1140 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1988 | 21 | 0.010 |
Why?
|
| Virulence | 1 | 1988 | 51 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1993 | 902 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2673 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1993 | 1293 | 0.000 |
Why?
|